At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 38 enrolled
Drug / intervention
Rebifdrug
Likely dose
Rebif 44 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group
In Brief
A Phase 4 clinical trial evaluating Rebif for Multiple Sclerosis. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartJun 2010
Primary CompletionFeb 2012
Study CompletionMar 2012
TodayJul 2026
First PostedMar 11, 2010
Enrollment StartJun 30, 2010
Primary CompletionFeb 29, 2012
Study CompletionMar 31, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.3 years ago
Interventions
Rebifdrug
44 mcg tiw